Research programme: cancer immunotherapy - Immunovative TherapiesAlternative Names: host-versus-tumour effect; MirrorEffect™
Latest Information Update: 25 Jul 2013
At a glance
- Originator Immunovative Therapies
- Class Cell therapies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 19 Jul 2013 Early research in Cancer in Israel (IV)